Clinical trial · Observational
Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy
NCT07075731CI-TRIAL-00118172recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to quantify the rates of cervical cancer screening and endometrial sampling prior to gender-affirming hysterectomy, assess the need for these tests in TGD individuals, and explore patient-centered options for these tests. By assessing the status of testing and correlation with hysterectomy pathology, this study will provide preliminary data on the current state of guideline-concordant care and provide initial evidence for the development of evidence-based guidelines in the future
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Screening | — | UNRESOLVED | — |
| Gender Diverse Populations | — | UNRESOLVED | — |
| Transgender | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Standard of Care Cancer Screening
- interventionNames
- Other: No intervention
- label
- FDA approved self swab
- interventionNames
- Other: No intervention
- label
- Mock self swab
- interventionNames
- Other: No intervention
Primary outcomes (2)
- measure
- Rates of cervical cancer screening and endometrial sampling in TGD individuals
- timeFrame
- Month 36
- description
- Describe the rates of cervical cancer screening and endometrial sampling in TGD individuals undergoing hysterectomy in the MHealth Fairview System between January 2014-June 2024.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years and older * Able to provide voluntary written consent prior to the performance of any research related activity. Patients who can provide informed consent * Able to understand, speak, read, and write in English * Patients who have undergone hysterectomy, or plan to have a hysterectomy * Patients who are transgender and gender diverse" Exclusion Criteria: * Opted out of research * \<18 years old * Lacks capacity to consent/has diminished capacity to consent * Cannot provide informed consent * Those on the study's community advisory board
References
Publications (0)
Data not yet available
No reference posted for this study.